Case closed: Neutrons settle 40-year debate on enzyme for drug design
Filter News
Area of Research
News Type
News Topics
- (-) Biomedical (1)
- 3-D Printing/Advanced Manufacturing (2)
- Bioenergy (2)
- Composites (1)
- Computer Science (1)
- Cybersecurity (1)
- Energy Storage (1)
- Environment (2)
- Isotopes (1)
- Materials Science (7)
- Microscopy (1)
- Nanotechnology (2)
- Neutron Science (6)
- Physics (1)
- Quantum Science (2)
- Sustainable Energy (2)
- Transportation (1)
Media Contacts
OAK RIDGE, Tenn., March 20, 2019—Direct observations of the structure and catalytic mechanism of a prototypical kinase enzyme—protein kinase A or PKA—will provide researchers and drug developers with significantly enhanced abilities to understand and treat fatal diseases and neurological disorders such as cancer, diabetes, and cystic fibrosis.